TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3654947

Group type: EXPERIMENTAL
Intervention: SV vaccine (one dose)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: SV vaccine (two doses)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: WV vaccine (one dose)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: WV vaccine (two doses)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Both vaccines (one or two doses)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Booster dose (one month after first dose)
Number of subjects: 104
Study: 29195125

Group type: EXPERIMENTAL
Intervention: STABLE + PHARM (ECT plus medications)
Number of subjects: 120

Group type: COMPARATOR
Intervention: PHARM (medications alone)
Number of subjects: 120
Study: 28134748

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 2600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2600
Study: 25314004

Group type: EXPERIMENTAL
Intervention: Calcium-collagen chelate (CC) dietary supplement (5g containing 500mg of elemental calcium and 200IU vitamin D)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (500mg of calcium and 200IU vitamin D)
Number of subjects: 39
Study: 23114538

Group type: EXPERIMENTAL
Intervention: Intensive glucose control (target blood glucose 80‐120 mg/dL)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional glucose control (target blood glucose <180 mg/dL)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional glucose control
Number of subjects: 67
Study: 21124762

Group type: EXPERIMENTAL
Intervention: IL-2 therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: cART only (control)
Number of subjects: 12
Study: 18474769

Group type: EXPERIMENTAL
Intervention: Low-vision rehabilitation program including low-vision examination, counseling, prescription and provision of low-vision devices, and 6 weekly sessions with a low-vision therapist.
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Low-vision rehabilitation program
Number of subjects: 126

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 126
Study: 16776699

Group type: EXPERIMENTAL
Intervention: Treadmill stress test in non-hypertensive cephalalgia sufferers (Ce)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Treadmill stress test in hypertensive cephalalgia sufferers (HyCe)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Treadmill stress test in healthy subjects (C)
Number of subjects: 150
Study: 14756604

Group type: EXPERIMENTAL
Intervention: Patient activation
Number of subjects: 159

Group type: COMPARATOR
Intervention: Passive education
Number of subjects: 159
Study: 10668769

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg orally three times a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study: 9493483

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study: 8095894

Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg + Prazosin 1 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Prazosin 1 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of drugs
Number of subjects: 8
Study: 3090959

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (1,500,000 U in 30 mn)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional heparin therapy
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 101
Study: 30996007

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks for up to 24 months
Number of subjects: 371
Study: 28460534

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR[BC]) program
Number of subjects: 322

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 322
Study: 25569529

Group type: EXPERIMENTAL
Intervention: Remote control injection system (Group B)
Number of subjects: 44
Study: 23031804

Group type: EXPERIMENTAL
Intervention: TEASAP (Treatment-Emergent Activation and Suicidality Assessment Profile)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: TEASAP Disinhibition subscale
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: TEASAP scores
Number of subjects: 56
Study: 21437615

Group type: EXPERIMENTAL
Intervention: Surgimesh WN (non‐woven polypropylene microfibre sheet)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Heavy weight polypropylene mesh
Number of subjects: 202
Study: 18070613

Group type: EXPERIMENTAL
Intervention: Delayed summaries
Number of subjects: 87

Group type: COMPARATOR
Intervention: Immediate summaries
Number of subjects: 87
Study: 16515651

Group type: EXPERIMENTAL
Intervention: Allergen application (Dermatophagoides farinae and Ctenocephalides felis)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline application (control)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Histological evaluation after allergen application
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Macroscopic and microscopic evaluations
Number of subjects: 7
Study: 15474758

Group type: EXPERIMENTAL
Intervention: 0.4 mg buccal estradiol
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 0.05, 0.1, 0.2 mg buccal estradiol
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 11195606

Group type: EXPERIMENTAL
Intervention: Metoprolol (50-100 mg twice daily)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Diltiazem (60-120 mg three times daily)
Number of subjects: 34
Study: 9421122

Group type: EXPERIMENTAL
Intervention: Dual therapy with ranitidine 300 mg b.i.d and clarithromycin 750 mg b.i.d, plus placebo (Group A)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Triple therapy with ranitidine 300 mg b.i.d and clarithromycin 750 mg b.i.d, plus lymecycline 300 mg b.i.d (Group B)
Number of subjects: 105
Study: 8050697

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bismuth 240 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg + Bismuth 240 mg
Number of subjects: 24
Study: 3430154

Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study: 30547732

Group type: EXPERIMENTAL
Intervention: PRETmax (5 stages at RPE 11, 13, 15, 17, 20)
Number of subjects: 10

Group type: COMPARATOR
Intervention: RAMP (0‐40 W + 5‐10 W · min‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PRETmax
Number of subjects: 10
Study: 27392728

Group type: EXPERIMENTAL
Intervention: Coping and Promoting Strength program (CAPS)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Information Monitoring (IM)
Number of subjects: 136
Study: 26364530

Group type: EXPERIMENTAL
Intervention: Self-management program based on INR monitoring
Number of subjects: 33

Group type: COMPARATOR
Intervention: General care (control group)
Number of subjects: 33
Study: 23547765

Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21422854

Group type: EXPERIMENTAL
Intervention: Metronidazole and erythromycin
Number of subjects: 269
Study: 19056608

Group type: EXPERIMENTAL
Intervention: Hypoglycemic clamp (2.8 mmol/l)
Number of subjects: 20
Study: 18273404

Group type: EXPERIMENTAL
Intervention: Home testing for chlamydia and gonorrhea
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinic testing for chlamydia and gonorrhea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home testing
Number of subjects: 0
Study: 15073266

Group type: EXPERIMENTAL
Intervention: (11)C-DASB
Number of subjects: 6

Group type: COMPARATOR
Intervention: (11)C-McN 5652
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both (11)C-DASB and (11)C-McN 5652
Number of subjects: 6
Study: 11437980

Group type: EXPERIMENTAL
Intervention: Caloric liquid meal with paracetamol administered orally without nasogastric tube
Number of subjects: 9

Group type: COMPARATOR
Intervention: Caloric liquid meal with paracetamol administered orally with nasogastric tube
Number of subjects: 9

Group type: COMPARATOR
Intervention: Gastric tube intervention
Number of subjects: 9
Study: 9709138

Group type: EXPERIMENTAL
Intervention: Awake group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anaesthetised group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mask group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (pooled groups)
Number of subjects: 60
Study: 8034208

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (3000 cGy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 60
Study: 2498089

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms kg‐1 1 min prior to induction of anaesthesia
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (16 patients)
Number of subjects: 21
Study: 4413081

Group type: EXPERIMENTAL
Intervention: Prednisone, 3 mg/kg per day for 10 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium salicylate, 100 mg/kg per day for 10 days
Number of subjects: 16
Study: 31765110

Group type: EXPERIMENTAL
Intervention: lisdexamfetamine 20 mg on Day 1, then 20 mg/d (Days 4-8), 50 mg/d (Days 9-13), 70 mg/d (Days 14-18)
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study: 30723954

Group type: EXPERIMENTAL
Intervention: Six web-based learning modules followed by two face-to-face group sessions
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 103
Study: 29972903

Group type: EXPERIMENTAL
Intervention: Corticotomy group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 26410620

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 150 mg/m² on days 1, 8, and 15 every 4 weeks
Number of subjects: 529

Group type: COMPARATOR
Intervention: dacarbazine 1000 mg/m² every 3 weeks
Number of subjects: 529
Study: 23465055

Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg once daily for the first 4 weeks, with an option to increase to 8 mg once daily for the remaining 8 weeks
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: fesoterodine treatment
Number of subjects: 322
Study: 21430035

Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus 10 mL every 60 minutes (10/60)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus 5 mL every 30 minutes (5/30)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus 2.5 mL every 15 minutes (2.5/15)
Number of subjects: 190
Study: 19301089

Group type: EXPERIMENTAL
Intervention: Risedronate (35 mg/week), calcium (1,000 mg/day), and vitamin D (400 IU/day) for 12 months
Number of subjects: 61

Group type: COMPARATOR
Intervention: Calcium (1,000 mg/day) and vitamin D (400 IU/day)
Number of subjects: 61
Study: 17049060

Group type: EXPERIMENTAL
Intervention: MMF with 50% dose reduction of CsA
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (maintenance CsA dose)
Number of subjects: 103
Study: 12775136

Group type: EXPERIMENTAL
Intervention: Oral montelukast
Number of subjects: 104

Group type: COMPARATOR
Intervention: Inhaled fluticasone propionate
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both montelukast and fluticasone
Number of subjects: 104
Study: 10848652

Group type: EXPERIMENTAL
Intervention: Rabeprazole 5 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 9322642

Group type: EXPERIMENTAL
Intervention: Cefetamet-pivoxil (2 gm single oral dose)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 8418401

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy plus optimal medical treatment (aspirin) (surgical group; n=211)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Optimal medical treatment alone (medical group; n=233)
Number of subjects: 444
Study: 3914180

Group type: EXPERIMENTAL
Intervention: Vitamin B-6 100 mg daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Vitamin B-6 100 mg daily and Placebo
Number of subjects: 34
Study: 30187345

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 396

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day
Number of subjects: 396
Study: 26931249

Group type: EXPERIMENTAL
Intervention: Cold dissection method
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bipolar dissection tonsillectomy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Laser tonsillectomy
Number of subjects: 96
Study: 23910233

Group type: EXPERIMENTAL
Intervention: One-third dose BCG
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Full dose BCG
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: 1 year of maintenance BCG
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: 3 years of maintenance BCG
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Overall treatment arms
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Chemical cystitis
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: General malaise
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Treatment stoppage due to side effects
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: 3 years of BCG
Number of subjects: 1316
Study: 22089885

Group type: EXPERIMENTAL
Intervention: Lung Volume Reduction Surgery (LVRS)
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Standard Multidisciplinary Medical Therapy (MT)
Number of subjects: 1086
Study: 16120033

Group type: EXPERIMENTAL
Intervention: Softsense meter (MediSense Products)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Optium meter (MediSense Products)
Number of subjects: 52
Study: 11535961

Group type: EXPERIMENTAL
Intervention: Antidepressants or counselling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-directive counselling, cognitive-behaviour therapy, or usual general practitioner care
Number of subjects: 0
Study: 9845864

Group type: EXPERIMENTAL
Intervention: High-structure, behaviorally oriented (HSB) counseling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-structure, facilitative (LSF) counseling
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both HSB and LSF counseling
Number of subjects: 60
Study: 7855658

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 77

Group type: COMPARATOR
Intervention: Organized smoking cessation program
Number of subjects: 77
Study: 2520783

Group type: EXPERIMENTAL
Intervention: Laminaria tent
Number of subjects: 519

Group type: COMPARATOR
Intervention: Hegar dilators
Number of subjects: 519
Study: 994315

Group type: EXPERIMENTAL
Intervention: fusaric acid calcium salt
Number of subjects: 5

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5
Study: 29475094

Group type: EXPERIMENTAL
Intervention: Sulthiame
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Children with recurrent seizures
Number of subjects: 43
Study: 27994503

Group type: EXPERIMENTAL
Intervention: Far-Infrared Radiation (FIR) therapy applied for 40 minutes during each hemodialysis session, three times per week for six months.
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no FIR therapy).
Number of subjects: 108
Study: 24126498

Group type: EXPERIMENTAL
Intervention: Modified gap-balancing technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional navigation-based TKA
Number of subjects: 40
Study: 21689141

Group type: COMPARATOR
Intervention: Triple therapy with amoxicillin, clarithromycin and lansoprazole twice daily for 2 weeks
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Dual therapy with amoxicillin and lansoprazole three times daily for 2 weeks
Number of subjects: 204

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 204
Study: 19887860

Group type: EXPERIMENTAL
Intervention: Breast-fed infants (BF)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Formula-fed infants (FF)
Number of subjects: 74
Study: 18955665

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg daily
Number of subjects: 26512
Study: 15901045

Group type: EXPERIMENTAL
Intervention: Coated tablet formulation A (5 mg finasteride)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Coated tablet formulation B (5 mg finasteride)
Number of subjects: 26
Study: 12682575

Group type: EXPERIMENTAL
Intervention: Snoezelen multisensory environment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normal 'quiet room' setting
Number of subjects: 26
Study: 10817796

Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8856392

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT) in obese patients
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Euglycemic‐hyperinsulinemic clamp in obese patients
Number of subjects: 19
Study: 1641497

Group type: EXPERIMENTAL
Intervention: Adjunctive imipramine added to ongoing medication regimen of fluphenazine decanoate and benztropine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Adjunctive imipramine
Number of subjects: 21
Study: 6405480

Group type: EXPERIMENTAL
Intervention: Immune serum globulin (ISG) administered to all subjects in group A (79% immunized)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Immune serum globulin (ISG) administered to 50% of subjects in group B (36% immunized)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-immunized control group (C)
Number of subjects: 100
Study: 30840773

Group type: EXPERIMENTAL
Intervention: PVB19 DNA testing using quantitative PCR
Number of subjects: 1500
Study: 28890353

Group type: EXPERIMENTAL
Intervention: Messages about arsenic, formaldehyde, lead, uranium, and ammonia
Number of subjects: 1148

Group type: EXPERIMENTAL
Intervention: Messages containing information on toxic products, health effects, or both
Number of subjects: 1148

Group type: EXPERIMENTAL
Intervention: Constituent-only messages referencing multiple constituents
Number of subjects: 1148
Study: 26847969

Group type: EXPERIMENTAL
Intervention: Actual CPAP
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 23
Study: 25256660

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg via subcutaneous injection into the abdomen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg via subcutaneous injection into the upper arm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg via subcutaneous injection into the thigh
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg via subcutaneous injection (all sites)
Number of subjects: 60
Study: 22429665

Group type: EXPERIMENTAL
Intervention: Behavioural intervention lasting for 10 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Number of subjects: 40
Study: 20425572

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control in type 2 diabetic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tight glycemic control in critically ill patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control in type 1 diabetic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tight glycemic control in critically ill patients (initial studies)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tight glycemic control in critically ill patients (subsequent studies)
Number of subjects: 0
Study: 17916813

Group type: EXPERIMENTAL
Intervention: Paramedic practitioner service active
Number of subjects: 3018

Group type: COMPARATOR
Intervention: Standard ambulance transfer and treatment
Number of subjects: 3018
Study: 16108890

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil plus leucovorin
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 12143944

Group type: EXPERIMENTAL
Intervention: Transdermal patch (n=149)
Number of subjects: 1291

Group type: EXPERIMENTAL
Intervention: Oral nitrates (n=504)
Number of subjects: 1291

Group type: EXPERIMENTAL
Intervention: Combination of oral and transdermal nitrates (n=60)
Number of subjects: 1291

Group type: COMPARATOR
Intervention: Nontreatment (n=578)
Number of subjects: 1291
Study: 9989541

Group type: EXPERIMENTAL
Intervention: DASH combination diet
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 459
Study: 7476284

Group type: EXPERIMENTAL
Intervention: Insulin/glucose infusion at 0.025/2.0 U/kg.h and mg/kg.min
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Insulin/glucose infusion at 0.050/3.5 U/kg.h and mg/kg.min
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Insulin/glucose infusion at 0.100/6.0 U/kg.h and mg/kg.min
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Insulin/glucose infusion at 0.200/8.0 U/kg.h and mg/kg.min
Number of subjects: 48
Study: 2179134

Group type: EXPERIMENTAL
Intervention: Cefotaxime at a dosage of 2 x 3 g/day for ten days
Number of subjects: 135

Group type: COMPARATOR
Intervention: Penicillin G at a dosage of 2 x 10 megaunits/day for ten days
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 135

Group type: COMPARATOR
Intervention: Penicillin G
Number of subjects: 135
Study: 450561

Group type: EXPERIMENTAL
Intervention: Oral safflower oil (1 gm/kg/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Addition of vitamin E (10 mg/kg/day) to safflower oil
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study: 30692241

Group type: EXPERIMENTAL
Intervention: Higher maternal DBP levels at delivery
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Higher cord blood 25(OH)D levels
Number of subjects: 189
Study: 28687375

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) of the resection cavity (within 30 days of surgery)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 132